IBM Watson for Oncology (2013–2018)
IBM marketed its Watson AI as recommending cancer treatments based on trained datasets, with Memorial Sloan Kettering as a launch partner. By 2017, investigations found Watson's recommendations were often based on hypothetical or unvalidated cases, and some hospitals reported unsafe advice.
IBM wound down Watson Health, selling parts in 2022; medical AI pivoted to narrower, rigorously validated tools.
A defining cautionary tale that high-stakes AI deployment requires clinical-grade validation, not just impressive demos.
LLMs for grid outage prediction face the same validation threshold: accuracy on historical data plus proven operational safety before a utility bets crews and dollars on them.
